Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66


Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Feb 7. doi: 10.1097/CAD.0000000000000596. [Epub ahead of print]


Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques.

Bergamaschi C, Watson DC, Valentin A, Bear J, Peer CJ, Figg WD Sr., Felber BK, Pavlakis GN.

Cytokine. 2018 Feb 2. pii: S1043-4666(18)30011-5. doi: 10.1016/j.cyto.2018.01.011. [Epub ahead of print]


Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.

Wang J, Yeung BZ, Cui M, Peer CJ, Lu Z, Figg WD, Guillaume Wientjes M, Woo S, Au JL.

J Control Release. 2017 Dec 28;268:147-158. doi: 10.1016/j.jconrel.2017.10.020. Epub 2017 Oct 18.


Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier.

Peer CJ, Chau CH, Figg WD.

Clin Cancer Res. 2017 Dec 15;23(24):7437-7439. doi: 10.1158/1078-0432.CCR-17-2741. Epub 2017 Oct 10.


Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system.

Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):521-536. doi: 10.1007/s10928-017-9543-z. Epub 2017 Sep 14.


A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.

Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC.

Cancer Chemother Pharmacol. 2017 Sep;80(3):645-652. doi: 10.1007/s00280-017-3382-x. Epub 2017 Jul 22.


Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.


Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.


Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects.

Rodgers L, Peer CJ, Figg WD.

Cancer Biol Ther. 2017 Jul 3;18(7):470-472. doi: 10.1080/15384047.2017.1323600. Epub 2017 May 5.


Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.


Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.

Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF.

Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2.


Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ, Shukla S, van Velkinburgh J, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, Venzon DJ, Brenner S, Lee W, Merino M, Luo J, Jager W, Price DK, Chau CH, Figg WD.

Mol Cancer Res. 2017 Aug;15(8):1096-1105. doi: 10.1158/1541-7786.MCR-16-0477. Epub 2017 Apr 7.


A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.

Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, Yarchoan R.

Oncologist. 2017 May;22(5):505-e49. doi: 10.1634/theoncologist.2016-0486. Epub 2017 Mar 24.


Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.

League-Pascual JC, Lester-McCully CM, Shandilya S, Ronner L, Rodgers L, Cruz R, Peer CJ, Figg WD, Warren KE.

J Neurooncol. 2017 May;132(3):401-407. doi: 10.1007/s11060-017-2388-x. Epub 2017 Mar 13.


Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response.

Backman JD, O'Connell JR, Tanner K, Peer CJ, Figg WD, Spencer SD, Mitchell BD, Shuldiner AR, Yerges-Armstrong LM, Horenstein RB, Lewis JP.

Pharmacogenet Genomics. 2017 Apr;27(4):159-163. doi: 10.1097/FPC.0000000000000272.


Pharmacokinetics of Pomalidomide in a Patient Receiving Hemodialysis Using a High-Cutoff Filter.

Dao K, Chtioui H, Lu Y, Peer CJ, Figg WD, Pruijm M, Buclin T, Kissling S.

Am J Kidney Dis. 2017 Apr;69(4):553-554. doi: 10.1053/j.ajkd.2016.10.026. Epub 2017 Jan 4. No abstract available.


Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.

Dao K, Lu Y, Peer CJ, Figg WD, Stadelmann R, Burnier M, Buclin T, Kissling S.

Cancer Chemother Pharmacol. 2017 Jan;79(1):215-218. doi: 10.1007/s00280-016-3219-z. Epub 2016 Dec 17.


Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.

Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, Sereti I, Maldarelli F, Whitby D, Marshall V, Goncalves PH, Khetani V, Figg WD, Steinberg SM, Zeldis JB, Yarchoan R.

J Clin Oncol. 2016 Dec;34(34):4125-4131. Epub 2016 Oct 31.


A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma.

Ferraz Nogueira Filho MA, Peer CJ, Nguyen J, McCalla A, Helman L, Figg WD.

J Pharm Biomed Anal. 2017 Jan 5;132:223-226. doi: 10.1016/j.jpba.2016.10.003. Epub 2016 Oct 5.


Pharmacogenomics and histone deacetylase inhibitors.

Goey AK, Sissung TM, Peer CJ, Figg WD.

Pharmacogenomics. 2016 Nov;17(16):1807-1815. Epub 2016 Oct 21. Review.


Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC.

Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.


ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.

O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, Bates SE.

Breast Cancer Res Treat. 2016 Nov;160(1):51-59. Epub 2016 Sep 12.


Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats.

Peer CJ, Strope JD, Beedie S, Ley AM, Holly A, Calis K, Farkas R, Parepally J, Men A, Fadiran EO, Scott P, Jenkins M, Theodore WH, Sissung TM.

Front Pharmacol. 2016 Aug 15;7:260. doi: 10.3389/fphar.2016.00260. eCollection 2016.


Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.

Wei BR, Michael HT, Halsey CH, Peer CJ, Adhikari A, Dwyer JE, Hoover SB, El Meskini R, Kozlov S, Weaver Ohler Z, Figg WD, Merlino G, Simpson RM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):643-655. doi: 10.1111/pcmr.12512. Epub 2016 Sep 22.


Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF.

Int J Cancer. 2016 Oct 1;139(7):1648-57. doi: 10.1002/ijc.30199. Epub 2016 Jun 27.


Synthesis of a stable and orally bioavailable englerin analogue.

Fash DM, Peer CJ, Li Z, Talisman IJ, Hayavi S, Sulzmaier FJ, Ramos JW, Sourbier C, Neckers L, Figg WD, Beutler JA, Chain WJ.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2641-4. doi: 10.1016/j.bmcl.2016.04.016. Epub 2016 Apr 8.


Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease.

Nicoli ER, Al Eisa N, Cluzeau CV, Wassif CA, Gray J, Burkert KR, Smith DA, Morris L, Cologna SM, Peer CJ, Sissung TM, Uscatu CD, Figg WD, Pavan WJ, Vite CH, Porter FD, Platt FM.

PLoS One. 2016 Mar 28;11(3):e0152007. doi: 10.1371/journal.pone.0152007. eCollection 2016.


UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.

Peer CJ, Goey AK, Sissung TM, Erlich S, Lee MJ, Tomita Y, Trepel JB, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

J Clin Pharmacol. 2016 Apr;56(4):450-60. doi: 10.1002/jcph.627. Epub 2015 Dec 4.


Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM.

Cancer. 2016 Feb 15;122(4):588-597. doi: 10.1002/cncr.29783. Epub 2015 Nov 13.


Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.

Rao M, Atay SM, Shukla V, Hong Y, Upham T, Ripley RT, Hong JA, Zhang M, Reardon E, Fetsch P, Miettinen M, Li X, Peer CJ, Sissung T, Figg WD, De Rienzo A, Bueno R, Schrump DS.

Clin Cancer Res. 2016 Mar 1;22(5):1197-210. doi: 10.1158/1078-0432.CCR-14-3379. Epub 2015 Oct 12.


Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.

Goey AK, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, Ehrlich S, Bryla C, Balasubramaniam S, Piekarz R, Steinberg SM, Bates SE, Figg WD.

J Clin Pharmacol. 2016 Apr;56(4):461-73. doi: 10.1002/jcph.625. Epub 2015 Nov 9.


Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.

Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, Ambrozak A, Gütschow M, Chau CH, Vargesson N, Figg WD.

Mol Cancer Ther. 2015 Oct;14(10):2228-37. doi: 10.1158/1535-7163.MCT-15-0320. Epub 2015 Aug 12.


A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.

Do K, Cao L, Kang Z, Turkbey B, Lindenberg ML, Larkins E, Holkova B, Steinberg SM, Raffeld M, Peer CJ, Figg WD, Eugeni M, Jacobs P, Choyke P, Wright JJ, Doroshow JH, Kummar S.

Clin Colorectal Cancer. 2015 Sep;14(3):154-61. doi: 10.1016/j.clcc.2015.02.007. Epub 2015 Mar 7.


Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.

Okoli TC, Peer CJ, Dunleavy K, Figg WD.

Cancer Biol Ther. 2015;16(2):204-6. doi: 10.1080/15384047.2014.1002369.


Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.

Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD Sr, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

J Clin Oncol. 2015 Jan 1;33(1):74-82. doi: 10.1200/JCO.2014.57.3329. Epub 2014 Nov 17.


Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, Fleisher TA, Turner M, Urquhart NE, Wharfe GH, Figg WD, Peer CJ, Goldman CK, Waldmann TA, Morris JC.

Clin Immunol. 2014 Dec;155(2):176-87. doi: 10.1016/j.clim.2014.09.012. Epub 2014 Sep 28.


An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.

Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS.

Clin Cancer Res. 2014 Dec 1;20(23):5918-26. doi: 10.1158/1078-0432.CCR-14-1143. Epub 2014 Sep 26.


Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.

Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S.

Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23.


Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application.

Roth J, Peer CJ, Widemann B, Cole DE, Ershler R, Helman L, Schrump D, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Nov 1;970:95-101. doi: 10.1016/j.jchromb.2014.08.021. Epub 2014 Sep 6.


A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, Peer CJ, Chen Y, Piekarz R, Steinberg SM, Trepel JB, Figg WD, Schrump DS, Giaccone G.

Clin Cancer Res. 2014 Nov 1;20(21):5392-402. doi: 10.1158/1078-0432.CCR-14-0968. Epub 2014 Sep 4.


Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy.

Shahbazi S, Peer CJ, Figg WD.

Cancer Biol Ther. 2014 Sep;15(9):1117-9. doi: 10.4161/cbt.29504. Epub 2014 Jun 11.


Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.

Horenstein RB, Madabushi R, Zineh I, Yerges-Armstrong LM, Peer CJ, Schuck RN, Figg WD, Shuldiner AR, Pacanowski MA.

J Clin Pharmacol. 2014 Aug;54(8):865-73. doi: 10.1002/jcph.293. Epub 2014 Apr 7.


Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.

Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs G, Peer CJ, Petros WP.

Cancer Chemother Pharmacol. 2014 May;73(5):991-7. doi: 10.1007/s00280-014-2432-x. Epub 2014 Mar 12.


A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.

Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, Figg WD.

J Pharm Biomed Anal. 2014 Apr;92:63-8. doi: 10.1016/j.jpba.2014.01.001. Epub 2014 Jan 9.


The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples.

Roth JE, Peer CJ, Price DK, Figg WD.

Cancer Biol Ther. 2014 Jan;15(1):16-8. doi: 10.4161/cbt.27149. Epub 2013 Nov 19.


A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma.

Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:107-12. doi: 10.1016/j.jchromb.2013.10.023. Epub 2013 Oct 22.


Uncovering the genetic landscape driving castration-resistant prostate cancer.

Martin TJ, Peer CJ, Figg WD.

Cancer Biol Ther. 2013 May;14(5):399-400. doi: 10.4161/cbt.24426.


The CYP2C19*17 variant is not independently associated with clopidogrel response.

Lewis JP, Stephens SH, Horenstein RB, O'Connell JR, Ryan K, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Mitchell BD, Shuldiner AR.

J Thromb Haemost. 2013 Sep;11(9):1640-6. doi: 10.1111/jth.12342.


Phase I trial of a new schedule of romidepsin in patients with advanced cancers.

Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL.

Clin Cancer Res. 2013 Aug 15;19(16):4499-507. doi: 10.1158/1078-0432.CCR-13-0095. Epub 2013 Jun 11.


A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.

Peer CJ, Rao M, Spencer SD, Shahbazi S, Steeg PS, Schrump DS, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 15;927:142-6. doi: 10.1016/j.jchromb.2013.01.003. Epub 2013 Jan 9.

Supplemental Content

Support Center